These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34959285)

  • 1. Immunotherapy for Triple-Negative Breast Cancer.
    Cao Y; Chen C; Tao Y; Lin W; Wang P
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Immunotherapy for Breast Cancer: A Review.
    Wen QE; Li L; Feng RQ; Li DH; Qiao C; Xu XS; Zhang YJ
    Breast Cancer (Dove Med Press); 2024; 16():497-516. PubMed ID: 39220564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present and Future of Immunotherapy for Triple-Negative Breast Cancer.
    Sriramulu S; Thoidingjam S; Speers C; Nyati S
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.
    Shewale H; Kanugo A
    Curr Pharm Biotechnol; 2024 Jul; ():. PubMed ID: 39092645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
    Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
    Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
    Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
    Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.
    Shi J; Liu F; Song Y
    Cancer Manag Res; 2020; 12():9375-9387. PubMed ID: 33061626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
    Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
    Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Singh S; Numan A; Maddiboyina B; Arora S; Riadi Y; Md S; Alhakamy NA; Kesharwani P
    Drug Discov Today; 2021 Jul; 26(7):1721-1727. PubMed ID: 33745879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
    Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
    Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MCL-1-targeted photosensitizer to combat triple-negative breast cancer with enhanced photodynamic efficacy, sensitization to ROS-induced damage, and immune response.
    Huang K; Yao H; Yan M; Zhang H; Yuan G; Wang Q; Xue J; Li J; Chen J
    J Inorg Biochem; 2022 Dec; 237():111997. PubMed ID: 36137402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.
    Elizabeth MS; Cristina SBJ; Christian CG
    Mini Rev Med Chem; 2024; 24(4):431-439. PubMed ID: 37198990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and challenges of immunotherapy in triple-negative breast cancer.
    Zhu Y; Zhu X; Tang C; Guan X; Zhang W
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.
    Llinàs-Arias P; Íñiguez-Muñoz S; McCann K; Voorwerk L; Orozco JIJ; Ensenyat-Mendez M; Sesé B; DiNome ML; Marzese DM
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.
    Marrufo AM; Mathew SO; Chaudhary P; Malaer JD; Vishwanatha JK; Mathew PA
    Am J Cancer Res; 2018; 8(6):1050-1063. PubMed ID: 30034942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.
    Stagg J; Allard B
    Ther Adv Med Oncol; 2013 May; 5(3):169-81. PubMed ID: 23634195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.